The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
GPNMB is a glycoprotein observed upon tissue damage and inflammation and is associated with astrocytes, microglia, and macrophages. Gene variations in GPNMB are linked with Parkinson’s disease (PD) risk, and changes in protein levels of GPNMB have been found in lysosomal storage disorders, including Gaucher’s disease with glucocerebrosidase (GCase) deficiency. In the current study, GPNMB increases were seen in the substantia nigra (SN) of PD patients compared to age-matched controls. Such PD patients have a decrease in GCase activity and corresponding elevation of glycosphingolipids in the SN (Rocha et al., 2015a). Interestingly, transgenic mice modeling synucleinopathy did not show GPNMB elevations or altered GCase activity levels compared to wild-type mice. However, upon CBE-induced GCase lysosomal dysfunction with elevated glycosphingolipids in wild-type mice, there were similar changes in GPNMB levels in the brain as seen in PD patient brains. These results indicate that GPNMB levels do not depend on alpha-synuclein load per se but relate directly to the lipidopathy changes induced by CBE-mediated GCase inhibition. The experimental modeling of elevating glycolipids resulted in GPNMB elevations with glial activation in several brain regions in mice. This is the first demonstration of region-specific elevations of GPNMB protein in Parkinson’s disease. The presence of GPNMB in PD patient substantia nigra, the induction of GPNMB after experimental glycosphingolipid increases, but not with pure alpha-synucleinopathy, point towards the potential for primary lipid-induced degeneration in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 2×
“chronic inflammatory phenotype, and this is dependent on TREM2APOE transcriptional regulation of a number of targets, GPNMB included, in microglia (Krasemann et al., 2017).”
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Glial Lipid Droplets and ROS Induced by Mitochondrial Defects Promote Neurodegeneration
Liu, L., Zhang, K., Sandoval, H., Yamamoto, S., Jaiswal, M., Sanz, E., Li, Z., Hui, J., Graham, B. H., Quintana, A., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.019 · Cited by 876 · cited 1×
“Elevation of reactive oxygen species and mitochondrial dysfunction in neurons leads to elevated lipid production in neurons and subsequent accumulation of lipid droplets, a lipid storage organelle, in glial cells (Liu et al., 2015).”
Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., & Masliah, E. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10231 · Cited by 502
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M. (2014) · Brain · doi:10.1093/brain/awt367 · Cited by 475 · cited 1×
“, 2015a), and has been associated with driving alpha-synuclein pathology (Mazzulli et al., 2011; Murphy et al., 2014).”
Neurodegenerative lysosomal disorders: A continuum from development to late age
Nixon, R. A., Yang, D.-S., & Lee, J.-H. (2008) · Autophagy · doi:10.4161/auto.6259 · Cited by 362
Koprich, J. B., Reske-Nielsen, C., Mithal, P., & Isacson, O. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-8 · Cited by 355
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346 · cited 3×
“However, mice modelling alpha-synucleinopathy (Thy1-aSYN) (Chesselet et al., 2012) do not show altered GCase”
Untangling the brain’s neuroinflammatory and neurodegenerative transcriptional responses
Srinivasan, K., Friedman, B. A., Larson, J. L., Lauffer, B. E., Goldstein, L. D., Appling, L. L., Borneo, J., Poon, C., Ho, T., Cai, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11295 · Cited by 336 · cited 3×
“Studies have identified transcriptional changes in GPNMB in rodent models of both PD and Alzheimer's disease (Kanaan et al., 2015; Srinivasan et al., 2016), and a recent report based on data mining techniques identified elevations of GPNMB mRNA in the substantia nigra of PD patients (Neal et al.,…”
Influential
Cited by
Bryois, J., Calini, D., Macnair, W., Foo, L., Urich, E., Ortmann, W., Iglesias, V. A., Selvaraj, S., Nutma, E., Marzin, M., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01128-z · Cited by 311
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
The Role of GPNMB in Inflammation
Saade, M., Araujo de Souza, G., Scavone, C., & Kinoshita, P. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674739 · Cited by 216
“org 5 An increase of GPNMB levels in the brain has also been detected in a diverse number of neurodegenerative diseases (in vitro, in vivo, and patients) such as AD (21), ALS (33, 34) and PD (53).”
BackgroundTrapecar, M., Wogram, E., Svoboda, D., Communal, C., Omer, A., Lungjangwa, T., Sphabmixay, P., Velazquez, J., Schneider, K., Wright, C. W., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd1707 · Cited by 176
GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein
Diaz-Ortiz, M. E., Seo, Y., Posavi, M., Carceles Cordon, M., Clark, E., Jain, N., Charan, R., Gallagher, M. D., Unger, T. L., Amari, N., et al. (2022) · Science · doi:10.1126/science.abk0637 · Cited by 158
Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice
Karikari, A. A., McFleder, R. L., Ribechini, E., Blum, R., Bruttel, V., Knorr, S., Gehmeyr, M., Volkmann, J., Brotchie, J. M., Ahsan, F., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.01.007 · Cited by 116
Van der Lienden, M. J. C., Gaspar, P., Boot, R., Aerts, J. M. F. G., & Van Eijk, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010066 · Cited by 84
“Elevated levels of GPNMB were also found in the substantia nigra (SN) of PD-patients [183,184].”
BackgroundA proteogenomic view of Parkinson’s disease causality and heterogeneity
Kaiser, S., Zhang, L., Mollenhauer, B., Jacob, J., Longerich, S., Del-Aguila, J., Marcus, J., Raghavan, N., Stone, D., Fagboyegun, O., et al. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00461-9 · Cited by 68
Androvic, P., Schifferer, M., Perez Anderson, K., Cantuti-Castelvetri, L., Jiang, H., Ji, H., Liu, L., Gouna, G., Berghoff, S. A., Besson-Girard, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39447-9 · Cited by 67
“GPNMB represents a genetic risk factor for Parkinson ’ s disease (PD) 55 , and is elevated in the substantia nigra of PDpatients 56 , andinspinalcords of amyotrophic lateralsclerosis(ALS) patients 57,58 .”
BackgroundMicroglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease
Satoh, J.-I., Kino, Y., Yanaizu, M., Tosaki, Y., Sakai, K., Ishida, T., & Saito, Y. (2017) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2017.01073 · Cited by 55
Mapping the serum proteome to neurological diseases using whole genome sequencing
Png, G., Barysenka, A., Repetto, L., Navarro, P., Shen, X., Pietzner, M., Wheeler, E., Wareham, N. J., Langenberg, C., Tsafantakis, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27387-1 · Cited by 55
The regulatory role of lipophagy in central nervous system diseases
Lan, Z.-Q., Ge, Z.-Y., Lv, S.-K., Zhao, B., & Li, C.-X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01504-z · Cited by 49
Root, J., Mendsaikhan, A., Taylor, G., Merino, P., Nandy, S., Wang, M., Araujo, L. T., Ryu, D., Holler, C., Thompson, B. M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114985 · Cited by 39
Peroxisomal defects in microglial cells induce a disease-associated microglial signature
Raas, Q., Tawbeh, A., Tahri-Joutey, M., Gondcaille, C., Keime, C., Kaiser, R., Trompier, D., Nasser, B., Leoni, V., Bellanger, E., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1170313 · Cited by 16
“Cathepsin B, progranulin, galectin-3, osteactivin and osteopontin are secreted proteins that have been found in biological fluid of patients suffering from neurodegenerative disorders (Kramer et al., 2016; Agah et al., 2018; Moloney et al., 2018; Batzu et al., 2019; Siew et al., 2019; Chai et al., 2021).”
Background
Metadata
- Authors
- Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O., & Hallett, P. J.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 120
- Pages
- 1-11
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2888541978
- Cited by
- 124
- References
- 13
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.